Advancements in Gene Editing and Cell-Based Therapies Propel U.S. Cell and Gene Therapy Market Growth.
The U.S. Cell and Gene Therapy Market was valued at USD 2.51 Billion in 2025 and is projected to reach USD 5.11 Billion by 2033, with a compound annual growth rate (CAGR) of 9.30% from 2027 to 2033.
The U.S. Cell and Gene Therapy Market is witnessing strong momentum, driven by rapid advancements in genetic engineering, increasing approvals of innovative therapies, and growing investments in regenerative medicine. The market is benefiting from rising adoption of personalized treatment approaches for cancer, rare genetic disorders, and chronic diseases, supported by favorable regulatory initiatives and expanding clinical trial activity.
Adeno-associated virus (AAV) vectors continue to dominate the vector segment due to their strong safety profile and high efficiency in gene delivery, while lentiviral vectors are gaining traction for ex vivo cell therapies, particularly CAR-T cell applications. Increasing collaboration between biotechnology companies, pharmaceutical manufacturers, academic institutions, and contract development and manufacturing organizations (CDMOs) is further accelerating product development and commercialization.
The oncology segment remains the largest application area, supported by the growing adoption of CAR-T therapies and continuous innovation in immunotherapy. Additionally, advancements in genome-editing technologies, including CRISPR-based platforms, are expanding the therapeutic potential of gene therapies across multiple disease indications.
Although the industry continues to face challenges such as high development and treatment costs, manufacturing complexity, reimbursement concerns, and stringent regulatory requirements, ongoing innovations in scalable manufacturing, automation, and quality control are helping address these barriers. Looking ahead, increasing healthcare expenditure, favorable regulatory support, and the expanding adoption of precision medicine are expected to sustain long-term market growth. The U.S. Cell and Gene Therapy Market is well positioned to redefine the future of healthcare by delivering innovative, potentially curative therapies that improve patient outcomes while creating substantial opportunities for industry participants over the forecast period.
Competitive Landscape
Some of the major companies operating within the Global Cell and Gene Therapy Market are Novartis AG, Gilead Sciences, Inc., Bristol Myers Squibb, Bluebird Bio, Vertex Pharmaceuticals, Sarepta Therapeutics, Krystal Biotech, Rocket Pharmaceuticals, CRISPR Therapeutics and Others.